OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) shares plunged more than 48% pre-market after the company said results from its Phase 3 SYNERGY trial to add custirsen to standard first-line treatment of docetaxel/prednisone in men with metastatic prostate cancer failed to meet primary endpoints. The stock which was halted from trading ahead of the news, recently changed hands…
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) presented an update on the company at the 26th Annual ROTH Conference at 12:30 p.m. PDT, March 11, 2014, at The Ritz-Carlton, Dana Point in California. Biota Pharmaceuticals Inc (NASDAQ:BOTA) stock performance was 10.15% in last session and finished the day at $6.62. Traded volume was 449,674 million shares in the…
CRT Capital Thursday morning ratings report included a coverage initiation by analyst Arlinda Lee on Oncogenex Pharmaceuticals (NASDAQ: OGXI) with a Buy rating and price target of $20. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) rose 8.88 percent to $13.85 yesterday on volume of 483,342million shares. The intra-day range of the stock was $12.61 to $13.95. OncoGenex Pharmaceuticals…
On 7 AUG OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced second quarter 2014 financial results. Revenue for the three and six months ended June 30, 2014 was $4.9 million and $16.7 million, respectively. This compares with $6.3 million and $11.4 million, respectively, in the same periods in 2013. Revenue earned in the second quarter of 2014 consists…
QUALCOMM, Inc. (NASDAQ:QCOM), NVIDIA Corporation (NASDAQ:NVDA) and Intel Corporation (NASDAQ:INTC) are the three new entrants that can significantly contribute in the Automotive Head-unit Processor Revenues. As per ABI Research, the three entrants can push the revenues to as much as $1.95 Billion by 2020. NVIDIA Corporation (NASDAQ:NVDA) belongs to Technology sector. Its net profit margin…
Cree, Inc. (Nasdaq: CREE), a market leader in LED lighting, today announced revenue of $436 million for its fourth quarter of fiscal 2014, ended June 29, 2014. This represents a 16% increase compared to revenue of $375 million reported for the fourth quarter of fiscal 2013, and an 8% increase compared to the third quarter…
